FDA “Study May Proceed” Notice and IND Clearance Received for the Evaluation of TBS-2025 in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
“As the only known company to advance a VISTA-inhibiting mAb through the FDA’s IND process into a Phase 1b study in mutNPM1 AML, this is a major milestone for the Company and a testament to our commitment to advancing novel therapies to address the unmet needs of patients with AML,” said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. “Research has shown that patients whose leukemic cells express VISTA have a poor response to therapy and significantly shorter survival. Studies have demonstrated that TBS-2025’s ability to block VISTA on leukemic cells has resulted in dramatic improvement in survival in studies of murine models of human AML, and we hope to translate this promising underlying science into a potentially safe and effective new treatment for patients with AML. We are excited for this next phase of our growth and by what it could mean for patients with AML.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the